Phase One trail of British Drugmaker AstraZeneca's coronavirus Antibody treatment has been started.
The trial will have 48 healthy participants in the UK, all aged between 18 to 55. In this phase, doctors will focus on the safety and tolerability of the drug called AZD7442. This drug is the amalgamation of two monoclonal antibodies taken from patients who had recovered from the coronavirus. According to the company, this vaccine contains antibodies that can protect people from the COVID-19 for at least six months.
Pangalos, executive vice president of biopharmaceuticals research and
development at AstraZeneca said "This trial is an important milestone in
the development of our monoclonal antibody combination to prevent or treat
"This combination of antibodies, coupled
with our proprietary half-life extension technology, has the potential to
improve both the effectiveness and durability of use and reduce the likelihood
of viral resistance."
is also working with the University of Oxford to develop a vaccine that can
generate immune responses on participants between ages 18 to 55 during an early
trial. There are no safety concerns with the vaccine, which showed positive
results just after two doses given to patients.
said, "One of the potential dangers if you prematurely let a vaccine out
is that it would make it difficult, if not impossible, for the other vaccines
to enroll people in their trial"
Fauci said, "One of the potential dangers if you prematurely let a vaccine out is that it would make it difficult, if not impossible, for the other vaccines to enroll people in their trial,"